Suciraslimab
Based on 1 Customer Validation
Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 97.42%
- CAS 番号: 2415439-63-1
- 分子量:146.16 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human IgG1 kappa
Human
|
IL-23 |
IL-12 |
IL-1β |
Suciraslimab (0.1 μg/mL; overnight) inhibits the secretion of interleukin-1β (IL-1β) induced by Amyloid β (Aβ) in human monocyte-derived microglia-like cells (MDMi) and PBMC[1].
Suciraslimab (0.1 μg/mL; 4 h) enhances phagocytosis of FITC-Aβ by the human microglial cell line HMC-3 and the Phorbol 12-myristate 13-acetate (HY-18739)-differentiated human oligodendrocyte cell line MO3.13[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human CD22 transgenic mice (C57BL/6JGpt-Cd22em1Cin(hCD22)/Gpt), male, 6-9 months old, with intracerebroventricular injection of oligomeric Aβ to induce neuroinflammation[1]
-
Dosage:15 mg/kg
-
Administration:Intravenous injection; once a week
-
Result:Restored spatial working memory.
Downregulated the expression of genes related to leukocyte migration and sialic acid binding in the brain.
Reduced the levels of chemokines such as CX3CL1, CCL24, and CCL4 in the cortex.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling Siglec-2/CD22 (red) with Suciraslimab (anti-Siglec-2/CD22) (HY-P990781). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody. -
Immobilized Siglec-2/CD22 Protein, Human can bind Suciraslimab. The EC50 for this effect is 4.412 ng/mL.
化学情報
-
CAS 番号 2415439-63-1
-
性状 Liquid
-
分子量 146.16 kDa
-
Color Colorless to light yellow
-
SMILES
[Suciraslimab]
-
別名
SM03
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Suciraslimab 関連分類
HY-P990781 関連分類
Powered by Bioz